Starling Oncology, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-60.6M | $-64.7M | $-83.1M | $152.0K | $-10.9M | $-14.3M |
| Depreciation & Amortization | $6.9M | $6.3M | $5.9M | $4.4M | $3.3M | $3.2M |
| Depreciation | $4.0M | $3.2M | $2.9M | $1.5M | $826.0K | $691.0K |
| Amortization | $3.0M | $3.1M | $3.0M | $2.9M | $2.5M | $2.5M |
| Stock-Based Compensation | $4.6M | $11.2M | $17.8M | $27.7M | $24.5M | $151.0K |
| Net Cash from Operating Activities | $-24.6M | $-26.5M | $-36.3M | $-61.8M | $-32.7M | $508.0K |
| Investing Activities | ||||||
| Capital Expenditures | $3.2M | $3.8M | $4.6M | $5.5M | $2.8M | $1.2M |
| Business Acquisitions | — | $0 | $4.5M | $8.6M | $9.1M | $150.0K |
| Net Cash from Investing Activities | $-3.1M | $46.2M | $62.6M | $-131.6M | $-12.2M | $-8.8M |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | $0 | $1.0M | $9.0M | $0 | — |
| Net Cash from Financing Activities | $11.6M | $-3.5M | $-6.8M | $92.2M | $154.0M | $11.9M |
| Net Change in Cash | — | — | — | — | — | — |
| Free Cash Flow | $-27.8M | $-30.3M | $-40.9M | $-67.3M | $-35.5M | $-686.0K |